Abstract
Androgen deprivation therapy (ADT) has been the standard of care for treating metastatic prostate cancer ever since the discovery that prostate cancer was an androgen-dependent disease in the 1940s. Since then, several therapeutic strategies have built on this basic principle to further improve survival, both through the use of additional systemic therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC) and with the addition of radiotherapy to the prostate in patients with low-volume mHSPC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
